Home › Graves Disease › NCT06980649
Study of BHV-1300 in Graves' Disease
RecruitingPhase 1
An Open-Label Biomarker Study of BHV-1300 in Graves' Disease
Who can join
Ages 18 to 65 · All sexes
Full eligibility criteria
Key Inclusion Criteria: 1\. Participants must have serologically confirmed Graves' Disease. Key Exclusion Criteria: 1. History of hyperthyroidism not caused by Graves' Disease (e.g., toxic adenoma or toxic multinodular goiter) and/or history of thyroid storm within six weeks of the Baseline visit. 2. History of treatment with radioactive iodine or thyroid surgery.
About the study
The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.
What is being tested
- BHV-1300 (drug)
Sponsor: Biohaven Therapeutics Ltd. · Participants: 15 · Started: Aug 21, 2025
Contact the study team
- Chief Medical Officer · Phone: 203-404-0410
Official record on ClinicalTrials.gov — NCT06980649
Locations in the U.S.
| California | Site-103, South Gate |
| Florida | Site-100, Miami |
| Georgia | Site-104, Columbus |
| North Carolina | Site-108, Greenville |
| Ohio | Site-110, Canton |
| Tennessee | Site-107, Memphis |
| Texas | Site-109, Dallas Site-101, Houston Site-106, Houston Site-105, Shavano Park |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.